title: Placenta-derived mesenchymal stem cells have an immunomodulatory effect that can control acute graft-versus-host disease in mice.
abstract: OBJECTIVE
  Immunomodulatory properties of mesenchymal stem cells (MSCs) have been applied to reduce the incidence of graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT). Among the various sources of MSCs that have immunomodulatory effects in vitro, only placenta-derived MSCs (PD-MSCs) have not been evaluated in an in vivo model of GVHD. In this study, we investigated the immunomodulatory properties of PD-MSCs in vitro and evaluated their clinical potential for controlling GVHD in an animal model.
  
  
  METHODS
  A GVHD animal model was established by transplanting C57BL/6 donor bone marrow cells and spleen cells into lethally irradiated BALB/c recipient mice. To control GVHD, human PD-MSCs were transplanted into recipient mice (5 × 10(5) or 1 × 10(6) cells).
  
  
  RESULTS
  PD-MSCs suppressed mitogen-stimulated T cell proliferation in vitro in a dose-dependent manner. Moreover, PD-MSCs inhibited cytokine secretion (interleukin-12, tumor necrosis factor-α and interferon-γ) of activated T cells. In vivo, the survival rate in the PD-MSC group (transplanted with 1 × 10(6) cells) was higher than that in the control group and histological scores were low in the PD-MSC group.
  
  
  CONCLUSIONS
  We present the first evidence that human PD-MSCs can efficiently control GVHD in an HSCT in vivo model.
authors.affiliation: Department of Internal Medicine, CHA Stem Cell Institute, Seoul, Korea.
authors.forename: Moon Ju
authors.initials: MJ
authors.lastname: Jang
authors.forename: Hye-Sun
authors.initials: HS
authors.lastname: Kim
authors.forename: Hye-Gyn
authors.initials: HG
authors.lastname: Lee
authors.forename: Gi Jin
authors.initials: GJ
authors.lastname: Kim
authors.forename: Hwang Gyun
authors.initials: HG
authors.lastname: Jeon
authors.forename: Hyun-Soo
authors.initials: HS
authors.lastname: Shin
authors.forename: Sei-Kyung
authors.initials: SK
authors.lastname: Chang
authors.forename: Gin-Hyung
authors.initials: GH
authors.lastname: Hur
authors.forename: So Young
authors.initials: SY
authors.lastname: Chong
authors.forename: Doyeun
authors.initials: D
authors.lastname: Oh
authors.forename: Hyung-Min
authors.initials: HM
authors.lastname: Chung
mesh_terms: D000818:Animals; D016026:Bone Marrow Transplantation / Q000276:immunology; D002454:Cell Differentiation; D004195:Disease Models, Animal; D005260:Female; D016195:G2 Phase; D006086:Graft vs Host Disease / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D056747:Immunomodulation; D007371:Interferon-gamma / Q000378:metabolism; D018664:Interleukin-12 / Q000378:metabolism; D008213:Lymphocyte Activation / Q000276:immunology; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D010920:Placenta / Q000166:cytology*; D011247:Pregnancy; D015996:Survival Rate; D013601:T-Lymphocytes / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12; D007371:Interferon-gamma